https://orcid.org/0000-0002-3412-7689
Citations (102)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Jiuhang Yu, Yichuang Yin, Yang Yu, Mengfei Cheng, Shuo Zhang, Shuai Jiang & Mei Dong. (2023) Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs. Immunopharmacology and Immunotoxicology 45:3, pages 386-394.
Read now
Read now
Stefano Bibbò, Gianluca Ianiro, Federica Giambò, Carlo Romano Settanni, Giovanni Cammarota & Antonio Gasbarrini. (2022) Role of gut microbiome on immunotherapy efficacy in melanoma. Human Vaccines & Immunotherapeutics 18:3.
Read now
Read now
Nadiya Hussain, Muntaha Naeem & David J. Pinato. (2021) Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. Human Vaccines & Immunotherapeutics 17:1, pages 55-61.
Read now
Read now
Pierre-Yves Cren, Nicolas Bertrand, Marie-Cécile Le Deley, Michaël Génin, Laurent Mortier, Pascal Odou, Nicolas Penel & Emmanuel Chazard. (2020) Is the survival of patients treated with ipilimumab affected by antibiotics? An analysis of 1585 patients from the French National hospital discharge summary database (PMSI). OncoImmunology 9:1.
Read now
Read now
Drew J. Schwartz, Olivia N. Rebeck & Gautam Dantas. (2019) Complex interactions between the microbiome and cancer immune therapy. Critical Reviews in Clinical Laboratory Sciences 56:8, pages 567-585.
Read now
Read now
Articles from other publishers (97)
John E. Niederhuber. 2024. Clinical Immuno-Oncology. Clinical Immuno-Oncology
223
236.e4
.
Anne-Gaëlle Goubet, Mathieu Rouanne, Lisa Derosa, Guido Kroemer & Laurence Zitvogel. (2023) From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology 20:11, pages 682-700.
Crossref
Crossref
Shiyu Li, Shuangli Zhu & Jun Yu. (2023) The role of gut microbiota and metabolites in cancer chemotherapy. Journal of Advanced Research.
Crossref
Crossref
Sung Wook Hwang, Min Kyu Kim & Mi-Na Kweon. (2023) Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review. Intestinal Research 21:4, pages 433-442.
Crossref
Crossref
David Dora, Glen J. Weiss, Zsolt Megyesfalvi, Gabriella Gállfy, Edit Dulka, Anna Kerpel-Fronius, Judit Berta, Judit Moldvay, Balazs Dome & Zoltan Lohinai. (2023) Computed Tomography-Based Quantitative Texture Analysis and Gut Microbial Community Signatures Predict Survival in Non-Small Cell Lung Cancer. Cancers 15:20, pages 5091.
Crossref
Crossref
Ciliang Guo, Lingkai Kong, Lingjun Xiao, Kua Liu, Huawei Cui, Qilei Xin, Xiaosong Gu, Chunping Jiang & Junhua Wu. (2023) The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies. Cell & Bioscience 13:1.
Crossref
Crossref
Gülin Alkan Şen, Nihan Şentürk Öztaş, Ezgi Değerli, Günay Can, Hande Turna & Mustafa Özgüroğlu. (2023) Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer. Lung Cancer 184, pages 107347.
Crossref
Crossref
Mengwei Zhang, Jinkai Liu & Qiang Xia. (2023) Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Experimental Hematology & Oncology 12:1.
Crossref
Crossref
Elio Gregory Pizzutilo, Rebecca Romanò, Laura Roazzi, Alberto G. Agostara, Sara Oresti, Annalisa Zeppellini, Laura Giannetta, Giulio Cerea, Diego Signorelli, Salvatore Siena & Andrea Sartore-Bianchi. (2023) Immune Checkpoint Inhibitors and the Exposome: Host-Extrinsic Factors Determine Response, Survival, and Toxicity. Cancer Research 83:14, pages 2283-2296.
Crossref
Crossref
Xiangdong Yan, Liuhui Bai, Ping Qi, Jin Lv, Xiaojing Song & Lei Zhang. (2023) Potential Effects of Regulating Intestinal Flora on Immunotherapy for Liver Cancer. International Journal of Molecular Sciences 24:14, pages 11387.
Crossref
Crossref
Ting Mei, Xuexi Yang, Min Yu, Xiaoman Tian, Qianyue Deng, Xianyan Chen & Youling Gong. (2022) Impact of antibiotic use before definitive concurrent chemoradiation in patients with locally advanced non-small cell lung cancer. Strahlentherapie und Onkologie 199:7, pages 645-657.
Crossref
Crossref
Alexander Rühle, Jiadai Zou, Ilinca Popp & Nils H. Nicolay. (2023) Authors’ response to the letter to the editor by Busra Yilmaz and Ugur Selek regarding our study “The influence of antibiotic administration on the outcomes of head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiation”. European Archives of Oto-Rhino-Laryngology 280:6, pages 3039-3040.
Crossref
Crossref
Lin-Yong Zhao, Jia-Xin Mei, Gang Yu, Lei Lei, Wei-Han Zhang, Kai Liu, Xiao-Long Chen, Damian Kołat, Kun Yang & Jian-Kun Hu. (2023) Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications. Signal Transduction and Targeted Therapy 8:1.
Crossref
Crossref
Maroun Bou Zerdan, Prashanth Ashok Kumar, Dulce M. Barrios, Alanna Glidden, Dayana Nasr, Stephanie Niforatos, Ghanshyam Ghelani, Jennifer Leibovitch, Sandy Nasr, Binod KC, Mulham Ombada, Farzam Khokhar, Bhavya Poudyal, Jenish Bhandari, Myera Shahnawaz, Stephen Graziano & Seah H. Lim. (2023) Metabolic syndrome is independently associated with improved overall survival to first-line therapy with immune checkpoint inhibitors in non-small cell lung cancer. Frontiers in Oncology 13.
Crossref
Crossref
Alya Heirali, Shirin Moossavi, Marie Claire Arrieta & Bryan Coburn. (2023) Principles and Terminology for Host–Microbiome–Drug Interactions. Open Forum Infectious Diseases 10:5.
Crossref
Crossref
Julien Colard-Thomas, Quentin Dominique Thomas & Marie Viala. (2023) Comedications with Immune Checkpoint Inhibitors: Involvement of the Microbiota, Impact on Efficacy and Practical Implications. Cancers 15:8, pages 2276.
Crossref
Crossref
Xing Cao, Yafei Wang, Wei Huang, Panyun Li, Chongjie Guo & Yuhui Li. (2023) The Impact of Concomitant Proton Pump Inhibitors Therapy on Clinical Outcome of Cancer Patients Treated With Immune Checkpoint Inhibitors. American Journal of Clinical Oncology 46:4, pages 142-149.
Crossref
Crossref
Athéna Crespin, Clément Le Bescop, Jean de Gunzburg, Fabien Vitry, Gérard Zalcman, Julie Cervesi & Pierre-Alain Bandinelli. (2023) A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Frontiers in Oncology 13.
Crossref
Crossref
Thomas Paz del Socorro, Marion Tonneau, David Pasquier & Mathias Chamaillard. (2023) Short- and Long-term Repercussions of Vancomycin on Immune Surveillance and the Efficacy of Antitumor Treatments. The Cancer Journal 29:2, pages 98-101.
Crossref
Crossref
Zhaoqing Yu, Li Qin & Guifang Yu. (2023) The progresses of relevant factors on the efficacy of immune checkpoint inhibitors in the non-small cell lung cancer patients. Cancer Treatment and Research Communications 37, pages 100758.
Crossref
Crossref
Ethan A. Burns, Kelly Gee, Ryan B. Kieser, Jiaqiong Xu, Yuqi Zhang, Aubrey Crenshaw, Ibrahim N. Muhsen, Charisma Mylavarapu, Abdullah Esmail, Shivan Shah, Godsfavour Umoru, Kai Sun, Carlo Guerrero, Zimu Gong, Kirk Heyne, Monisha Singh, Jun Zhang, Eric H. Bernicker & Maen Abdelrahim. (2022) Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer. Cancers 15:1, pages 81.
Crossref
Crossref
Małgorzata Frąk, Anna Grenda, Paweł Krawczyk, Janusz Milanowski & Ewa Kalinka. (2022) Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients. Cancers 14:22, pages 5577.
Crossref
Crossref
Nobuaki Ochi, Hiromichi Yamane & Nagio Takigawa. (2022) Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer免疫チェックポイント阻害薬の効果予測因子. Haigan 62:5, pages 355-362.
Crossref
Crossref
Maroun Bou Zerdan, Joseph Kassab, Paul Meouchy, Elio Haroun, Rami Nehme, Morgan Bou Zerdan, Gracia Fahed, Michael Petrosino, Dibyendu Dutta & Stephen Graziano. (2022) The Lung Microbiota and Lung Cancer: A Growing Relationship. Cancers 14:19, pages 4813.
Crossref
Crossref
Alireza Tojjari, Hassan Abushukair & Anwaar Saeed. (2022) The Crosstalk between Microbiome and Immunotherapeutics: Myth or Reality. Cancers 14:19, pages 4641.
Crossref
Crossref
Wenjie Zhang, Jie Zhang, Tian Liu, Juan Xing, Huan Zhang, Daorong Wang & Dong Tang. (2022) Bidirectional effects of intestinal microbiota and antibiotics: a new strategy for colorectal cancer treatment and prevention. Journal of Cancer Research and Clinical Oncology 148:9, pages 2387-2404.
Crossref
Crossref
Shanshan Yang, Suya Zhao, Yixiang Ye, Liqun Jia & Yanni Lou. (2022) Global research trends on the links between gut microbiota and cancer immunotherapy: A bibliometric analysis (2012-2021). Frontiers in Immunology 13.
Crossref
Crossref
Gulcin Tezcan, Mohammad Alsaadi, Shaimaa Hamza, Ekaterina E. Garanina, Ekaterina V. Martynova, Gulshat R. Ziganshina, Elina R. Farukshina, Albert A. Rizvanov & Svetlana F. Khaiboullina. (2022) Azithromycin and Ceftriaxone Differentially Activate NLRP3 in LPS Primed Cancer Cells. International Journal of Molecular Sciences 23:16, pages 9484.
Crossref
Crossref
Marina Vitorino, Diogo Alpuim Costa, Rodrigo Vicente, Telma Caleça & Catarina Santos. (2022) Local Breast Microbiota: A “New” Player on the Block. Cancers 14:15, pages 3811.
Crossref
Crossref
Jiaxin Zhou, Guowei Huang, Wan-Ching Wong, Da-hai Hu, Jie-wen Zhu, Ruiman Li & Hong Zhou. (2022) The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors. Frontiers in Immunology 13.
Crossref
Crossref
N. Tinsley, C. Zhou, S. Nahm, S. Rack, G.C.L. Tan, P. Lorigan, F. Blackhall & N. Cook. (2022) Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer. ESMO Open 7:3, pages 100430.
Crossref
Crossref
Yingying Li, Shiyuan Wang, Mengmeng Lin, Chunying Hou, Chunyu Li & Guohui Li. (2022) Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy. Frontiers of Medicine 16:3, pages 307-321.
Crossref
Crossref
Zihui Meng, Zixuan Ye, Pengrong Zhu, Jianguo Zhu, Shuguang Fang, Tianzhu Qiu, Yanan Li & Lijuan Meng. (2022) New Developments and Opportunities of Microbiota in Treating Breast Cancers. Frontiers in Microbiology 13.
Crossref
Crossref
Dayana Nasr, Mahmoudreza Moein, Stephanie Niforatos, Sandy Nasr, Mulham Ombada, Farzam Khokhar, Myera Shahnawaz, Bhavya Poudyal, Maroun Bou Zerdan, Dibyendu Dutta, Reza F. Saidi & Seah H. Lim. (2022) Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation. Journal of Clinical Medicine 11:10, pages 2726.
Crossref
Crossref
Takuya Minamishima, Hirotake Hida, Masayuki Miyazaki, Shunsuke Kon, Koji Senzaki, Taku Nagai & Kiyofumi Yamada. (2022) Influence of Antibiotic Use on the Effectiveness and Safety of Immune Checkpoint Inhibitors免疫チェックポイント阻害薬の有効性および安全性に対する抗菌薬使用の影響. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 48:5, pages 173-193.
Crossref
Crossref
Kentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, Shohei Koyama, Yujiro Naito, Akio Osa, Takashi Hirai, Hidekazu Suzuki, Norio Okamoto, Takayuki Shiroyama, Kazumi Nishino, Yuichi Adachi, Takuro Nii, Yumi Kinugasa-Katayama, Akiko Kajihara, Takayoshi Morita, Seiya Imoto, Satoshi Uematsu, Takuma Irie, Daisuke Okuzaki, Taiki Aoshi, Yoshito Takeda, Toru Kumagai, Tomonori Hirashima & Atsushi Kumanogoh. (2022) Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer. JCI Insight 7:9.
Crossref
Crossref
Mingming Tian, Si Zhang, Yujen Tseng, Xizhong Shen, Ling Dong & Ruyi Xue. (2022) Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy. Anti-Cancer Agents in Medicinal Chemistry 22:7, pages 1244-1256.
Crossref
Crossref
Kangning Peng, Ken Chen, Benjamin A. Teply, Gary C. Yee, Paraskevi A. Farazi & Elizabeth R. Lyden. (2021) Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Annals of Pharmacotherapy 56:4, pages 377-386.
Crossref
Crossref
Ghada Araji, Julian Maamari, Fatima Ali Ahmad, Rana Zareef, Patrick Chaftari & Sai-Ching Jim Yeung. (2022) The Emerging Role of the Gut Microbiome in the Cancer Response to Immune Checkpoint Inhibitors: A Narrative Review. Journal of Immunotherapy and Precision Oncology 5:1, pages 13-25.
Crossref
Crossref
Maroun Bou Zerdan, Stephanie Niforatos, Sandy Nasr, Dayana Nasr, Mulham Ombada, Savio John, Dibyendu Dutta & Seah H. Lim. (2022) Fecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice. Cancers 14:3, pages 691.
Crossref
Crossref
Howard Junca, Dietmar H. Pieper & Eva Medina. (2022) The emerging potential of microbiome transplantation on human health interventions. Computational and Structural Biotechnology Journal 20, pages 615-627.
Crossref
Crossref
Eiko Hayase & Robert R. Jenq. (2021) Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. Genome Medicine 13:1.
Crossref
Crossref
Xinyi Liu, Yanjie Chen, Si Zhang & Ling Dong. (2021) Gut microbiota-mediated immunomodulation in tumor. Journal of Experimental & Clinical Cancer Research 40:1.
Crossref
Crossref
Jie Zhang, Zhujiang Dai, Cheng Yan, Wenjie Zhang, Daorong Wang & Dong Tang. (2021) A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics. Clinical and Translational Oncology 23:12, pages 2415-2430.
Crossref
Crossref
Quentin Giordan, Julia Salleron, Catherine Vallance, Clothilde Moriana & Christelle Clement-Duchene. (2021) Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. Frontiers in Immunology 12.
Crossref
Crossref
Kyungchan Min, Seok Joong Yun, Hansoo Park & Yun-Sok Ha. (2021) Microbiome of Genitourinary Tumors: Especially in Prostate Cancer and Kidney Cancer. The Korean Journal of Urological Oncology 19:3, pages 136-147.
Crossref
Crossref
Mara Cruellas, Alfonso Yubero, María Zapata, Eva M. Galvez, Marta Gascón, Dolores Isla, Rodrigo Lastra, Luis Martínez-Lostao, Maitane Ocariz, Julián Pardo, Ariel Ramírez, Andrea Sesma, Irene Torres-Ramón & José Ramón Paño. (2021) How Could Antibiotics, Probiotics, and Corticoids Modify Microbiota and Its Influence in Cancer Immune Checkpoint Inhibitors: A Review. Infection and Immunity 89:9.
Crossref
Crossref
Priyanka Patel, Arisa Poudel, Sunam Kafle, Manusha Thapa Magar & Ivan Cancarevic. (2021) Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors. Cureus.
Crossref
Crossref
Huazhen Lu, Qingzhuo Wang, Wenzheng Liu, Zhiqiang Wen & Yanan Li. (2021) Precision strategies for cancer treatment by modifying the tumor-related bacteria. Applied Microbiology and Biotechnology 105:16-17, pages 6183-6197.
Crossref
Crossref
Youssef Bouferraa, Andrea Chedid, Ghid Amhaz, Ahmed El Lakkiss, Deborah Mukherji, Sally Temraz & Ali Shamseddine. (2021) The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. International Journal of Molecular Sciences 22:15, pages 8036.
Crossref
Crossref
Sally Temraz, Farah Nassar, Firas Kreidieh, Deborah Mukherji, Ali Shamseddine & Rihab Nasr. (2021) Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. International Journal of Molecular Sciences 22:15, pages 7800.
Crossref
Crossref
Agnieszka Beata Malczewski, Natkunam Ketheesan, Jermaine I. G. Coward & Severine Navarro. (2021) Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites. Frontiers in Immunology 12.
Crossref
Crossref
S. Ghanem, C.J. Kim, D. Dutta, M. Salifu & S.H. Lim. (2021) Antimicrobial therapy during cancer treatment: Beyond antibacterial effects. Journal of Internal Medicine 290:1, pages 40-56.
Crossref
Crossref
Cheng-Bei Zhou, Yi-Lu Zhou & Jing-Yuan Fang. (2021) Gut Microbiota in Cancer Immune Response and Immunotherapy. Trends in Cancer 7:7, pages 647-660.
Crossref
Crossref
Matthew K. Wong, Philip Barbulescu, Bryan Coburn & Elaine Reguera-Nuñez. (2021) Therapeutic interventions and mechanisms associated with gut microbiota-mediated modulation of immune checkpoint inhibitor responses. Microbes and Infection 23:6-7, pages 104804.
Crossref
Crossref
Baohua Luo, Yongbin Zhang, Caiqin Zhang, Xiaoqiu Liu & Changhong Shi. (2021) Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. Cancer Letters 509, pages 53-62.
Crossref
Crossref
Uqba Khan, Kaylee Ho, Eun Kyeong Hwang, Cristian Peña, Julianna Brouwer, Katherine Hoffman, Doron Betel, Gregory F. Sonnenberg, Bishoy Faltas, Ashish Saxena, Kaitlin Eng Weisiger, Sarah Oh, Erika Hissong, Arindam RoyChoudhury & Manish A. Shah. (2021) Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. American Journal of Clinical Oncology 44:6, pages 247-253.
Crossref
Crossref
Maria-Luisa Schubert, Roman Rohrbach, Michael Schmitt & Christoph K. Stein-Thoeringer. (2021) The Potential Role of the Intestinal Micromilieu and Individual Microbes in the Immunobiology of Chimeric Antigen Receptor T-Cell Therapy. Frontiers in Immunology 12.
Crossref
Crossref
Qiang Dong, Eric S. Chen, Chen Zhao & Chengcheng Jin. (2021) Host-Microbiome Interaction in Lung Cancer. Frontiers in Immunology 12.
Crossref
Crossref
Indranil Chattopadhyay, Deeptashree Nandi & Alo Nag. (2021) The pint- sized powerhouse: Illuminating the mighty role of the gut microbiome in improving the outcome of anti- cancer therapy. Seminars in Cancer Biology 70, pages 98-111.
Crossref
Crossref
Maria Tsikala-Vafea, Neel Belani, Kendra Vieira, Hina Khan & Dimitrios Farmakiotis. (2021) Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. International Journal of Infectious Diseases 106, pages 142-154.
Crossref
Crossref
Nobuaki Ochi, Eiki Ichihara, Nagio Takigawa, Daijiro Harada, Koji Inoue, Takuo Shibayama, Shinobu Hosokawa, Daizo Kishino, Shingo Harita, Naohiro Oda, Naofumi Hara, Katsuyuki Hotta, Yoshinobu Maeda & Katsuyuki Kiura. (2021) The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression. European Journal of Cancer 149, pages 73-81.
Crossref
Crossref
Csilla Oláh, Melinda Váradi, Orsolya Horváth, Péter Nyirády & Tibor Szarvas. (2021) A béltartalom és a vizelet mikrobiom-összetételének onkológiai vonatkozásai. Orvosi Hetilap 162:15, pages 579-586.
Crossref
Crossref
Po‐Hsien Lu, Tzu‐Cheng Tsai, John Wen‐Cheng Chang, Shin‐Tarng Deng & Chi‐Yuan Cheng. (2020) Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia. Journal of Clinical Pharmacy and Therapeutics 46:2, pages 408-414.
Crossref
Crossref
Chengliang Huang, Meizhang Li, Ben Liu, Huanbo Zhu, Qun Dai, Xianming Fan, Kathan Mehta, Chao Huang, Prakash Neupane, Fen Wang, Weijing Sun, Shahid Umar, Cuncong Zhong & Jun Zhang. (2021) Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review. Frontiers in Oncology 11.
Crossref
Crossref
Angelo Castello, Sabrina Rossi, Luca Toschi & Egesta Lopci. (2021) Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. Journal of Clinical Medicine 10:6, pages 1251.
Crossref
Crossref
Qing Wu, Junjin Liu, Sumei Wu & Xianhe Xie. (2021) The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. International Immunopharmacology 92, pages 107303.
Crossref
Crossref
Marc Oliva, Nuria Mulet-Margalef, Maria Ochoa-De-Olza, Stefania Napoli, Joan Mas, Berta Laquente, Laia Alemany, Eric Duell, Paolo Nuciforo & Victor Moreno. (2021) Tumor-Associated Microbiome: Where Do We Stand?. International Journal of Molecular Sciences 22:3, pages 1446.
Crossref
Crossref
Yang Yu, Peng Zheng, Lei Gao, Haiyuan Li, Pengxian Tao, Dengfeng Wang, Fanghui Ding, Qianling Shi & Hao Chen. (2021) Effects of Antibiotic Use on Outcomes in Cancer Patients Treated Using Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Journal of Immunotherapy 44:2, pages 76-85.
Crossref
Crossref
Jahan J Mohiuddin, Brian Chu, Andrea Facciabene, Kendra Poirier, Xingmei Wang, Abigail Doucette, Cathy Zheng, Wei Xu, Emily J Anstadt, Ravi K Amaravadi, Giorgos C Karakousis, Tara C Mitchell, Alexander C Huang, Jacob E Shabason, Alexander Lin, Samuel Swisher-McClure, Amit Maity, Lynn M Schuchter & John N Lukens. (2021) Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy. JNCI: Journal of the National Cancer Institute 113:2, pages 162-170.
Crossref
Crossref
Saad KhanRuth HauptmanLibusha Kelly. (2021) Engineering the Microbiome to Prevent Adverse Events: Challenges and Opportunities. Annual Review of Pharmacology and Toxicology 61:1, pages 159-179.
Crossref
Crossref
Daniel V. Araujo, Geoffrey A. Watson, Marc Oliva, Alya Heirali, Bryan Coburn, Anna Spreafico & Lillian L. Siu. (2021) Bugs as drugs: The role of microbiome in cancer focusing on immunotherapeutics. Cancer Treatment Reviews 92, pages 102125.
Crossref
Crossref
Dibyendu Dutta & Seah H. Lim. (2020) Bidirectional interaction between intestinal microbiome and cancer: opportunities for therapeutic interventions. Biomarker Research 8:1.
Crossref
Crossref
Wolfgang M. Brueckl, Joachim H. Ficker & Gloria Zeitler. (2020) Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC). BMC Cancer 20:1.
Crossref
Crossref
Mengxue Yang, Ying Wang, Man Yuan, Mingyang Tao, Cheng Kong, Hao Li, Jiandong Tong, Huiyuan Zhu & Xuebing Yan. (2020) Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis. International Immunopharmacology 88, pages 106876.
Crossref
Crossref
David J. Pinato. (2020) Antibiotic-induced Dysbiosis as a Putative Actionable Driver of Cancer Immunity in Renal Cell Carcinoma. European Urology 78:2, pages 207-208.
Crossref
Crossref
Dimitrios Farmakiotis. (2020) The Human Microbiome and Checkpoint Inhibition: Potential Benefits From Antibiotic Stewardship. Clinical Infectious Diseases 71:3, pages 701-702.
Crossref
Crossref
E. I. Olekhnovich, A. I. Manolov, A. V. Pavlenko, D. N. Konanov, D. E. Fedorov, P. O. Tikhonova, O. E. Glushchenko & E. N. Ilina. (2020) The Effect of Intestinal Microbiome on the Effectiveness of Antitumor Immunotherapy. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry 14:3, pages 241-251.
Crossref
Crossref
Gaia Giannone, Eleonora Ghisoni, Sofia Genta, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto & Giorgio Valabrega. (2020) Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. International Journal of Molecular Sciences 21:12, pages 4414.
Crossref
Crossref
Joshua S. Davis, David Ferreira, Emma Paige, Craig Gedye & Michael Boyle. (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clinical Microbiology Reviews 33:3.
Crossref
Crossref
Fausto Petrelli, Alessandro Iaculli, Diego Signorelli, Antonio Ghidini, Lorenzo Dottorini, Gianluca Perego, Michele Ghidini, Alberto Zaniboni, Stefania Gori & Alessandro Inno. (2020) Survival of Patients Treated with Antibiotics and Immunotherapy for Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 9:5, pages 1458.
Crossref
Crossref
Huilin Xu, Ximing Xu, Huimin Wang, Wei Ge & Dedong Cao. (2020) The association between antibiotics use and outcome of cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology 149, pages 102909.
Crossref
Crossref
Brooke E. Wilson, Bertrand Routy, Adnan Nagrial & Venessa T. Chin. (2019) The effect of antibiotics on clinical outcomes in immune-checkpoint blockade: a systematic review and meta-analysis of observational studies. Cancer Immunology, Immunotherapy 69:3, pages 343-354.
Crossref
Crossref
E.I. Olekhnovich, A.I. Manolov, A.V. Pavlenko, D.N. Konanov, D.E. Fedorov, P.O. Tikhonova, O.E. Glushchenko & E.N. Ilina. (2020) Intestinal microbiom modulates the response to antitumor immunotherapy. Biomeditsinskaya Khimiya 66:1, pages 54-63.
Crossref
Crossref
Nadina Tinsley, Cong Zhou, Grace Tan, Samuel Rack, Paul Lorigan, Fiona Blackhall, Matthew Krebs, Louise Carter, Fiona Thistlethwaite, Donna Graham & Natalie Cook. (2020) Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. The Oncologist 25:1, pages 55-63.
Crossref
Crossref
Lena Gaissmaier & Petros Christopoulos. (2020) Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration 99:11, pages 903-929.
Crossref
Crossref
Ewan A Langan, Victoria Graetz, Judith Allerheiligen, Detlef Zillikens, Jan Rupp & Patrick Terheyden. (2020) Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. The Lancet Oncology 21:1, pages e55-e65.
Crossref
Crossref
Khalid El Bairi, Mariam Amrani & Adil Maleb. 2020. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing
111
145
.
David J. Pinato, Daria Gramenitskaya, Daniel M. Altmann, Rosemary J. Boyton, Benjamin H. Mullish, Julian R. Marchesi & Mark Bower. (2019) Antibiotic therapy and outcome from immune-checkpoint inhibitors. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Crossref
Hyunho Kim, Ji Eun Lee, Sook Hee Hong, Myung Ah. Lee, Jin Hyoung Kang & In-Ho Kim. (2019) The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer 19:1.
Crossref
Crossref
A. Elkrief, L. Derosa, G. Kroemer, L. Zitvogel & B. Routy. (2019) The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. Annals of Oncology 30:10, pages 1572-1579.
Crossref
Crossref
Fyza Y. Shaikh, Joell J. Gills & Cynthia L. Sears. (2019) Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. EBioMedicine 48, pages 642-647.
Crossref
Crossref
Giovanni Rossi, Aldo Pezzuto, Claudio Sini, Alessandro Tuzi, Fabrizio Citarella, Michael G. McCusker, Olga Nigro, Enrica Tanda & Alessandro Russo. (2019) Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario. Critical Reviews in Oncology/Hematology 142, pages 26-34.
Crossref
Crossref
Romain Villéger, Amélie Lopès, Guillaume Carrier, Julie Veziant, Elisabeth Billard, Nicolas Barnich, Johan Gagnière, Emilie Vazeille & Mathilde Bonnet. (2019) Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?. International Journal of Molecular Sciences 20:18, pages 4584.
Crossref
Crossref
Huemer, Lang, Westphal, Gampenrieder, Hutarew, Weiss, Hackl, Lamprecht, Rinnerthaler & Greil. (2019) Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade. Journal of Clinical Medicine 8:7, pages 1014.
Crossref
Crossref
Florian Scotté, Raffaele Ratta & Philippe Beuzeboc. (2019) Side effects of immunotherapy: a constant challenge for oncologists. Current Opinion in Oncology 31:4, pages 280-285.
Crossref
Crossref
Arthur E. Frankel, Sachin Deshmukh, Amit Reddy, John Lightcap, Maureen Hayes, Steven McClellan, Seema Singh, Brooks Rabideau, T. Grant Glover, Bruce Roberts & Andrew Y. Koh. (2019) Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota. Integrative Cancer Therapies 18, pages 153473541984637.
Crossref
Crossref